scholarly journals Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

2017 ◽  
Vol 6 (7) ◽  
pp. 1552-1562 ◽  
Author(s):  
Bikram Shrestha ◽  
Yifei Sun ◽  
Farzana Faisal ◽  
Victoria Kim ◽  
Kevin Soares ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Benefit ◽  
Newly Diagnosed ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Term Survival ◽  
Long Term Survival ◽  
Borderline Resectable Pancreatic Cancer

Phase I/II trial of neoadjuvant chemoradiotherapy with 5-FU, cisplatin, mitomycin C, and heparin for borderline resectable pancreatic cancer.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 315-315
Author(s):  
Taizo Hibi ◽  
Minoru Kitago ◽  
Koichi Aiura ◽  
Minoru Tanabe ◽  
Osamu Itano ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Mitomycin C ◽  
Curative Resection ◽  
Neoadjuvant Chemoradiotherapy ◽  
Advanced Pancreatic Cancer ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer ◽  
Disease Free

315 Background: Because of the high incidence of local recurrence and liver metastasis, long-term outcomes of patients following resection of advanced pancreatic cancer are extremely poor. Facilitation of curative resection and prevention of micrometastasis are the goals of neoadjuvant therapy. We evaluated the feasibility and efficacy of our neoadjuvant chemoradiotherapy (NACRT) protocol for borderline resectable pancreatic cancer patients. Methods: During the period between 2003 and 2011, 24 patients with borderline resectable pancreatic cancers underwent NACRT comprising 5-FU (300 mg/body/day, day 1−5/week for 4 weeks), cisplatin (10mg/body day2, 9, 16, 23), mitomycin C (4mg/body/day, day 1, 8, 15, and 22), heparin (6000 IU/body/day for 4 weeks), and radiation (2 Gy/day, day 1−5/week for 4 weeks, total 40 Gy). They were reevaluated for resectability after therapy. Primary endpoints were toxicity and overall patient and disease-free survivals. Secondary endpoint was the ratio of microscopically margin negative resection. Results: All 24 patients completedNACRT. Grade 3−4 hematological adverse events were observed in 9 (38%) patients but none developed severe gastrointestinal toxicity. In 7 (29%) patients, restaging revealed distant metastasis or local disease progression not amenable to curative resection. The remaining 17 patients (71%) underwent surgery (pancreatoduodenectomy, 13 and distal pancreatectomy, 4) with zero 30-day postoperative or in-hospital mortality. The 5-year overall all patient and disease-free survival rates after pancreatectomy were 52.6% and 36.3%, respectively. Postoperative histopathological evaluation demonstrated a marked degenerative change in the specimen, achieving negative surgical margins in 15/17 (88%) patients and pathological complete response in the remaining 2 (12%) patients. Conclusions: Our NACRT protocol is feasible with a low toxicity profile and an excellent curative resection rate in the treatment of borderline resectable pancreatic cancer. It is a promising regimen associated with improved long-term prognoses than historical controls.

Long-Term Survival after Multimodality Treatment for Resectable Pancreatic Cancer

2000 ◽  
Vol 27 (3) ◽  
pp. 217-224 ◽  
Author(s):  
Hideo Ozaki ◽  
Taira Kinoshita ◽  
Tomoo Kosuge ◽  
Kazuaki Shimada ◽  
Junji Yamamoto ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Multimodality Treatment ◽  
Resectable Pancreatic Cancer ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival

2016 ◽  
Vol 8 (3) ◽  
pp. 248 ◽  
Author(s):  
Marianne Sinn ◽  
Marcus Bahra ◽  
Timm Denecke ◽  
Sue Travis ◽  
Uwe Pelzer ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Treatment Options ◽  
Resectable Pancreatic Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Perioperative Treatment

A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer

Surgery ◽  
2017 ◽  
Vol 161 (4) ◽  
pp. 930-938 ◽  
Author(s):  
Daniel Delitto ◽  
Sarah M. Judge ◽  
Thomas J. George ◽  
George A. Sarosi ◽  
Ryan M. Thomas ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Resectable Pancreatic Cancer ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Extended Venous Resections for Borderline Resectable Pancreatic Head Adenocarcinoma—A Retrospective Studies of Nine Cases

Healthcare ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 978
Author(s):  
Nicolae Bacalbasa ◽  
Irina Balescu ◽  
Mihai Dimitriu ◽  
Cristian Balalau ◽  
Florentina Furtunescu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Portal Vein ◽  
Radical Surgery ◽  
Portal Vein Resection ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Venous Resection ◽  
Graft Thrombosis ◽  
Borderline Resectable Pancreatic Cancer ◽  
Vein Resection

Background: pancreatic cancer is one of the most lethal malignancies and a leading cause of cancer-related death worldwide. The only chance to improve the long-term outcomes of patients with pancreatic cancer is surgery with radical intent. Methods: in the present paper, we aim to describe a case series of 9 patients submitted to radical surgery for borderline resectable pancreatic cancer. Results: in all cases, negative resection margins were achieved. The types of venous resection consisted of tangential portal vein resection in four cases, circumferential portal vein resection with direct reanastomosis in one case and circumferential resection with graft placement in another four cases; postoperatively, one patient developed a vascular surgery-related complication consisting of graft thrombosis and thus necessitated prolonged anticoagulant therapy. Conclusions: extended venous resections can be a safe and efficient way to maximize the benefits of radical surgery in locally advanced, borderline resectable pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document